GENE logo

GENE

Profile

Full Name

Genetic Technologies Limited

Ticker Symbol

GENE

Exchange

NASDAQ

Sector

Healthcare

Industry

Diagnostics & Research

Country

Australia

IPO

September 6, 2005

Indexes

Not included

Website

http://genetype.com

Employees

55

Key Details

Price

$0.77(0.00%)

Market cap

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$5.02M(-14.02% YoY)

Annual EPS

-$0.02(+23.50% YoY)

PE ratio

-

Next earnings date

N/A

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$0.77
GENE price is $0.77

30-Day Relative Volume

-
GENE 30-day relative volume value is unknown

Price Performance

Price Most recent change

0%
GENE {parameterFullLabel} has remained unchanged on Apr 17, 2025

Price YTD change

0%
GENE {parameterFullLabel} has remained unchanged since January 1st

Price 1-year change

-75.79%
GENE price is down -75.79% year-on-year

Price 3-year change

-91.55%
GENE price is down -91.55% over the past 3 years

Price Range

Price All-time high

$1385.00
GENE price is currently -99.94% below its historical high of $1385.00

Price 3-year low

$0.67
GENE price is currently +14.18% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$3.71M
GENE market capitalization is $3.71 million

Market cap 3-year change

-86.69%
GENE market capitalization is down -86.69% over the past 3 years

Market cap All-time high

$179.22M
GENE market capitalization is currently -97.93% below its historical high of $179.22 million

Market cap sector rank

10.37%
GENE market capitalization is higher than 10.37% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+25.99%
GENE shares outstanding is up +25.99% year-on-year

Shares Outstanding 3-Year Change

+57.48%
GENE shares outstanding is up +57.48% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

0.10
GENE beta is 0.10

200-day SMA

$0.80
GENE price is currently -4.58% below its 200-day simple moving average

50-day SMA

$0.77
GENE price is currently equal to its 50-day simple moving average

RSI

50.00
GENE 14-day relative strength index is 50.00

Volume

-
GENE 30-day relative volume value is unknown

ATR

$0.00
GENE average true range is $0.00

10-day Historical Volatility

0.00%
GENE 10-day historical volatility is 0.00%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$5.02M
GENE annual revenue is $5.02 million

Revenue Analysts estimate

-
GENE annual revenue consensus analysts' forecast is unknown

Revenue 1-year change

-14.02%
GENE annual revenue is down -14.02% year-on-year

Revenue Sector rank

21.75%
GENE annual revenue is higher than 21.75% of companies in Healthcare sector

EPS

EPS

-$0.02
GENE annual earnings per share is -$0.02

EPS Analysts estimate

-
GENE annual earnings per share consensus analysts' forecast is unknown

EPS 1-year change

+23.5%
GENE annual earnings per share is up +23.5% year-on-year

EPS Sector rank

81.69%
GENE annual earnings per share is higher than 81.69% of companies in Healthcare sector

Profit

Gross profit

$2.56M
GENE annual gross profit is $2.56 million

Gross margin

50.94%
GENE annual gross profit margin is 50.94%

Operating profit

-$8.00M
GENE annual operating income is -$8.00 million

Operating margin

-159.30%
GENE annual operating profit margin is -159.30%

Net income

-$7.88M
GENE annual net profit is -$7.88 million

Net margin

-156.78%
GENE annual net profit margin is -156.78%

Expenses

Total expenses

$13.03M
GENE annual total expenses is $13.03 million

Operating expenses

$10.56M
GENE annual total operating expenses is $10.56 million

Cost of goods sold

$2.47M
GENE annual cost of goods sold is $2.47 million

Selling, general & administrative expenses

$8.41M
GENE annual SGA is $8.41 million

Depreciation and amortization

-
GENE annual depreciation & amortization value is unknown

Interest expense

$33.80K
GENE annual interest expense is $33.80 thousand

Income tax

$0.00
GENE annual income tax is $0.00

EBIT & EBITDA

EBIT

-$7.84M
GENE annual earnings before interest & taxes is -$7.84 million

EBITDA

-$7.49M
GENE annual EBITDA is -$7.49 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$4.14M
GENE annual total assets is $4.14 million

Non current assets

$1.67M
GENE annual long term assets is $1.67 million

Current assets

$2.47M
GENE annual total current assets is $2.47 million

Cash and cash equivalents

$682.20K
GENE annual cash & cash equivalents is $682.20 thousand

Accounts receivable

$139.90K
GENE annual accounts receivable is $139.90 thousand

Inventory

$138.00K
GENE annual inventory is $138.00 thousand

Liabilities

Total liabilities

$2.91M
GENE annual total liabilities is $2.91 million

Long term liabilities

$107.40K
GENE annual total long term liabilities is $107.40 thousand

Current liabilities

$2.80M
GENE annual total current liabilities is $2.80 million

Accounts payable

$974.60K
GENE annual accounts payable is $974.60 thousand

Debt

Total debt

$585.00K
GENE annual total debt is $585.00 thousand

Total debt 1-year change

+65.86%
GENE annual total debt is up +65.86% year-on-year

Long term debt

$15.30K
GENE annual long term debt is $15.30 thousand

Short term debt

$569.70K
GENE annual short term debt is $569.70 thousand

Equity & Capital

Shareholders equity

$1.22M
GENE annual stockholders equity is $1.22 million

Book value

$1.22M
GENE annual book value is $1.22 million

Retained earnings

-$111.21M
GENE annual retained earnings is -$111.21 million

Working capital

-$334.30K
GENE annual working capital is -$334.30 thousand

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-
GENE annual cash flow from operations value is unknown

Cash from operations 1-year change

-
GENE annual cash flow from operations 1-year change is unknown

Cash from investing

$75.30K
GENE annual cash flow from investing activities is $75.30 thousand

Cash from investing 1-year change

+135.87%
GENE annual cash flow from investing activities is up +135.87% year-on-year

Cash from financing

$1.85M
GENE annual cash flow from financing activities is $1.85 million

Cash from financing 1-year change

-53.55%
GENE annual cash flow from financing activities is down -53.55% year-on-year

CAPEX

CAPEX

$21.60K
GENE annual capital expenditures is $21.60 thousand

CAPEX 1-year change

+83.05%
GENE annual capital expenditures is up +83.05% year-on-year

Free Cash Flow

Free cash flow

-
GENE annual free cash flow value is unknown

Free cash flow 1-year change

-
GENE annual free cash flow 1-year change is unknown

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

50.94%
GENE annual gross profit margin is 50.94%

Operating margin

-159.30%
GENE annual operating profit margin is -159.30%

Net margin

-156.78%
GENE annual net profit margin is -156.78%

ROA & ROE

ROA

-112.80%
GENE annual return on assets is -112.80%

ROE

-182.95%
GENE annual return on equity is -182.95%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
GENE price to earnings ratio value is unknown

PE ratio Sector rank

-
GENE price to earnings ratio is unknown

PB Ratio

PB ratio

3.03
GENE price to book ratio is 3.03

PB ratio Sector rank

72.46%
GENE price to book ratio is higher than 72.46% of companies in Healthcare sector

PS Ratio

PS ratio

-
GENE price to sales ratio value is unknown

PS ratio Sector rank

-
GENE price to sales ratio is unknown

Enterprise value

Enterprise value

$3.61M
GENE enterprise value is $3.61 million

Enterprise value Sector rank

17.36%
GENE enterprise value is higher than 17.36% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-
GENE EV/EBITDA value is unknown

EV/EBITDA Sector rank

-
GENE EV/EBITDA is unknown

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

0.88
GENE annual current ratio is 0.88

Quick ratio

0.83
GENE annual quick ratio is 0.83

Leverage

Debt to equity

0.35
GENE annual debt to equity ratio is 0.35

Interest coverage ratio

-232.08
GENE annual interest coverage ratio is -232.08

Risk & Stability

Piotroski F-Score

-
GENE piotroski f-score value is unknown

Altman Z-Score

-42.03
GENE altman z-score is -42.03

Analyst ratings

Recent major analysts updates

Nov 25, 20 Ladenburg Thalmann
Sell
Nov 16, 12 Ladenburg Thalmann
Sell

Institutional Ownership

Similar stocks

SNOA logo
Sonoma Pharmaceuticals (SNOA)
KTTA logo
Pasithea Therapeutics (KTTA)
ATIP logo
ATI Physical Therapy (ATIP)
XBIO logo
Xenetic Biosciences (XBIO)
MBIO logo
Mustang Bio (MBIO)
RHE logo
Regional Health Properties (RHE)
TOVX logo
Theriva Biologics (TOVX)
XYLO logo
Xylo Technologies (XYLO)
JAGX logo
Jaguar Health (JAGX)
  • What is the ticker symbol for Genetic Technologies Limited?
  • Does Genetic Technologies Limited pay dividends?
  • What sector is Genetic Technologies Limited in?
  • What industry is Genetic Technologies Limited in?
  • What country is Genetic Technologies Limited based in?
  • When did Genetic Technologies Limited go public?
  • Is Genetic Technologies Limited in the S&P 500?
  • Is Genetic Technologies Limited in the NASDAQ 100?
  • Is Genetic Technologies Limited in the Dow Jones?
  • When was Genetic Technologies Limited's last earnings report?
  • When does Genetic Technologies Limited report earnings?

What is the ticker symbol for Genetic Technologies Limited?

The ticker symbol for Genetic Technologies Limited is NASDAQ:GENE

Does Genetic Technologies Limited pay dividends?

No, Genetic Technologies Limited does not pay dividends

What sector is Genetic Technologies Limited in?

Genetic Technologies Limited is in the Healthcare sector

What industry is Genetic Technologies Limited in?

Genetic Technologies Limited is in the Diagnostics & Research industry

What country is Genetic Technologies Limited based in?

Genetic Technologies Limited is headquartered in Australia

When did Genetic Technologies Limited go public?

Genetic Technologies Limited's initial public offering (IPO) was on September 6, 2005

Is Genetic Technologies Limited in the S&P 500?

No, Genetic Technologies Limited is not included in the S&P 500 index

Is Genetic Technologies Limited in the NASDAQ 100?

No, Genetic Technologies Limited is not included in the NASDAQ 100 index

Is Genetic Technologies Limited in the Dow Jones?

No, Genetic Technologies Limited is not included in the Dow Jones index

When was Genetic Technologies Limited's last earnings report?

Genetic Technologies Limited's most recent earnings report was on Apr 17, 2025

When does Genetic Technologies Limited report earnings?

The date for Genetic Technologies Limited's next earnings report has not been announced yet
On this page